Description |
Product Type |
Product Size |
Tablets |
30'S |
Product Company |
PMS Pharma |
Letrozole 2.5mg |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Getz Pharma |
Trastuzumab 440mg/10ml |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Martin Dow |
Ondansetron 8mg/4ml |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Atezolizumab 1200mg/20ml |
Product Type |
Product Size |
Tablet |
60'S |
Product Company |
Pharma Solution |
Erlotinib 150mg |
Product Type |
Product Size |
Capsules |
100'S |
Product Company |
Pharmedic |
Hydroxyurea 500mg |
Content | Letrozole is a medicine used for treating breast cancer. It can also help prevent breast cancer coming back. It is mainly prescribed for women who have been through the menopause and have a type of cancer called "hormone-dependent" breast cancer.
| Trastuzumab is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. | Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. | "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | Erlotinib is an EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. | Hydroxyurea is in a class of medications called antimetabolites. Hydroxyurea treats cancer by slowing or stopping the growth of cancer cells in your body. Hydroxyurea treats sickle cell anemia by helping to prevent formation of sickle-shaped red blood cells. |
Reviews
There are no reviews yet.